GCT1046-01 (Genmab)
Description: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
Target Patient Population: Currently in Expansion with the following target populations: NSCLC (PD-1/L1 pre-treated or naïve)
Study Design: Study drug is given IV every 21 days.